Loading…
Chinese pharmaceutical and health-products conglomerate (Haiwang brand) spanning generics, nutraceuticals and pharmacy retail.
Chinese pharmaceutical and health-products conglomerate (Haiwang brand) spanning generics, nutraceuticals and pharmacy retail.
Sells prescription drugs to hospitals, largely through Livzon Pharmaceutical Group, a separately listed drugmaker it controls, and sells nutraceuticals and health products to consumers through pharmacies and retail channels under its Haiwang brand. Livzon's own shares trade separately in Shenzhen and Hong Kong.
Moat: narrow (brand, distribution). Established Haiwang consumer brand plus a diversified generics/retail distribution network.
Headquarters: Shenzhen, China · Employees: 13,575
Size Joincare Pharmaceutical Group Industry (600380.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.86B, the 899th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.53 on 6 Nov 2026.
Performance Over six months the shares fell 3.7%, against -2.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 11.8% over the last twelve months (peer median +16.5%); the operating margin is 17.6% (peer median 11.3%).
Valuation It trades at 15.6× forward earnings against a peer median of 44.2× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥13.4B | CN¥15.1B | CN¥15.5B | CN¥16.5B | CN¥17.0B |
| Revenue growth | — | -3% | -6% | -3% | — |
| Gross profit | CN¥8.38B | CN¥9.12B | CN¥9.40B | CN¥9.65B | CN¥10.4B |
| EBITDA | n/a | CN¥3.89B | CN¥4.17B | CN¥4.28B | CN¥4.08B |
| Net income | CN¥1.13B | CN¥1.34B | CN¥1.39B | CN¥1.44B | CN¥1.50B |
| Free cash flow | CN¥3.04B | CN¥3.16B | CN¥2.68B | CN¥2.95B | CN¥2.97B |
| Capital expenditure | CN¥709M | CN¥767M | CN¥979M | CN¥1.13B | CN¥1.15B |
| Total debt | CN¥5.80B | CN¥5.50B | CN¥6.68B | CN¥7.40B | CN¥7.08B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Joincare Pharmaceutical Group Industry 600380.SS | $2.86B | -4% | -12% | 18% | 15.6× | -13.1% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| By-health 300146.SZ | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600380.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.4% | +1.2% | 6th highest of 21 |
| 6-month return | -3.7% | -2.8% | 10th lowest of 21 |
| Distance from 52-week high | -18.1% | -26.7% | 8th highest of 21 |
| Revenue growth (TTM) | -11.8% | +16.5% | 5th lowest of 20 |
| Operating margin | 17.6% | 11.3% | 8th highest of 20 |
| Forward P/E | 15.6× | 44.2× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -13.1% | 25.7% | least demanding of 14 |
| Growth delivered (Del g) | +2.4% | +14.0% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | -15.5 pp | +2.0 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | +4.3 pp | +0.9 pp | 6th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 15.6× | -13.1% | +2.4% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | n/a | n/a | n/a |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 76.2× | 50.7% | +17.3% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 100.0× | 42.1% | +22.9% |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 53.4× | 25.7% | +100.1% |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | n/a | n/a | n/a |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 30.6× | 7.3% | +6.5% |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 64.9× | 45.0% | +27.7% |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% | +14.0% |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | n/a | n/a | n/a |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 26.3× | 4.6% | +4.8% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 54.3× | n/a | n/a |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% | +6.1% |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 21.3× | -2.2% | +7.0% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% | +19.3% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% | -9.6% |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 37.9× | 48.9% | +367.3% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | n/a | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 61.8× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% | +2.7% |